Posting this because the summary going around does not say what the paper says, and the difference matters for how people here are using it.
Freezing is the one to avoid, and freeze-thaw more so. Ice-crystal formation and the concentration changes at the phase boundary drive aggregation, and aggregated peptide does not recover on thawing. A vial that has been frozen and thawed is not rescued by returning it to the fridge.
Where I think it is weakest: the follow-up is short relative to how long people actually take these drugs, so durability is an assumption here rather than a finding.
What would genuinely help is knowing what a temperature excursion actually does, and what distinguishes an unopened vial from one already in use. Numbers rather than impressions, if you have them.
Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.